Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,501.65 -12.72 -0.08%
S&P 500 1,875.39 -4.16 -0.22%
NASDAQ 4,126.97 -34.49 -0.83%
Ticker Volume Price Price Delta
STOXX 50 3,175.97 -23.72 -0.74%
FTSE 100 6,674.74 -7.02 -0.11%
DAX 9,544.19 -55.90 -0.58%
Ticker Volume Price Price Delta
NIKKEI 14,404.99 -141.28 -0.97%
TOPIX 1,164.90 -8.91 -0.76%
HANG SENG 22,525.74 16.10 0.07%

InfuSystem Receives Contract Offers for Infusion Pumps in All Nine Markets Put out to Bid by the Centers for Medicare & Medicaid



  InfuSystem Receives Contract Offers for Infusion Pumps in All Nine Markets
  Put out to Bid by the Centers for Medicare & Medicaid Services (“CMS”)

                   Company Reaffirms Prior Revenue Guidance

Business Wire

MADISON HEIGHTS, Mich. -- October 3, 2013

InfuSystem Holdings, Inc. (NYSE MKT: INFU) (“InfuSystem” or the “Company”), a
leading national provider of infusion pumps and related services for the
healthcare industry in the United States, said that it has received offers to
provide external infusion pumps and supplies in all nine of the Metropolitan
Statistical Areas (“MSAs”) put out to bid by CMS.

The MSAs include: Charlotte, Cincinnati, Cleveland, Dallas, Kansas City,
Orlando, Miami, Pittsburgh, and Riverside (CA).

“While these nine MSAs selected by CMS only represent approximately 1% of our
Company’s current revenues, we are extremely pleased that our winning bids
were in line with and some cases exceeded our expectations,” stated InfuSystem
Chief Executive Officer Eric Steen. “It says a great deal about the quality of
the entire InfuSystem team and our understanding of the changing national
medical care environment.”

Mr. Steen also reaffirmed that the Company’s recent guidance of high single
digit revenue growth in 2014 has not changed. “We continue to believe that
competitive bidding will create opportunities for those companies that are
efficient enough to capitalize on them. InfuSystem offers the most
cost-effective model to deliver infusion therapy at home as an extension of
in-clinic infusion therapy. The Affordable Care Act ensures that this market
will continue to expand, especially for treatment of multiple therapies and
disease states.”

About InfuSystem Holdings, Inc.

InfuSystem Holdings, Inc. is a leading provider of infusion pumps and related
services to hospitals, oncology practices and other alternate site healthcare
providers. Headquartered in Madison Heights, Michigan, the Company delivers
local, field-based customer support and also operates Centers of Excellence in
Michigan, Kansas, California, and Ontario, Canada. The Company’s stock is
traded on the NYSE MKT under the symbol INFU.

Forward-Looking Statements

Certain statements contained in this release are forward-looking statements
and are based on future expectations, plans and prospects for InfuSystem
Holdings, Inc.’s (“InfuSystem”, “INFU”, “the Company”, “We”) business and
operations that involve a number of risks and uncertainties. The Company’s
outlook for 2013 and other forward-looking statements in this release are made
as of August 29, 2013, and the Company disclaims any duty to supplement,
update or revise such statements on a going-forward basis, whether as a result
of subsequent developments, changed expectations or otherwise. In connection
with the “safe harbor” provisions of the Private Securities Litigation Reform
Act of 1995, the Company is identifying certain factors that could cause
actual results to differ, perhaps materially, from those indicated by these
forward-looking statements. Those factors, risks and uncertainties include,
but are not limited to, potential changes in overall healthcare reimbursement
– including CMS competitive bidding, sequestration, concentration of
customers, increased focus on early detection of cancer, competitive
treatments, dependency on Medicare Supplier Number, availability of
chemotherapy drugs, global financial conditions, changes and enforcement of
state and federal laws, natural forces, competition, dependency on suppliers,
risks in acquisitions & joint ventures, US Healthcare Reform, relationships
with healthcare professionals and organizations, technological changes related
to infusion therapy, dependency on websites and intellectual property, the
ability of the Company to successfully integrate acquired businesses,
dependency on key personnel, dependency on banking relations and covenants,
and other risks associated with our common stock, as well as any other
litigation to which the Company may be subject from time to time; and other
risk factors as discussed in the Company’s annual report on Form 10-K for the
year ended December 31, 2012 and in other filings made by the Company from
time to time with the Securities and Exchange Commission.

Additional information about InfuSystem Holdings, Inc. is available at
www.infusystem.com.

Contact:

The Dilenschneider Group
Rob Swadosh / Patrick Malone
212-922-0900
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement